TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jun 03, 2022 16:37 JST
Source:
Eisai
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
TOKYO, Jun 03, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.
Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).
"DAYVIGO continues to serve as an important asset to Eisai's neurology portfolio and we look forward to presenting the findings from several analyses at this year's SLEEP Meeting," said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. "Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability,(1),(2) and causes distress or impairs functioning in social and occupational settings. Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs."
(1) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(2) Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10
About Lemborexant (product name: DAYVIGO)
Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.
For more information, visit www.eisai.com/news/2022/news202244.html.
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
April 21 2026 19:52 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
March 27 2026 19:14 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
March 27 2026 17:19 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
March 23 2026 10:19 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
March 19 2026 09:54 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
March 17 2026 18:49 JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
March 12 2026 16:21 JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
March 11 2026 11:07 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
More Press release >>
Latest Press Release
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 00:23 JST
Honda to Begin Sales of Super-ONE Compact EV
May 22, 2026 00:16 JST
Fujitsu supports the Panasonic Group in accelerating its sustainability management through the implementation of a CFP calculation solution
May 21, 2026 13:57 JST
Sharp Launches Poketomo Conversational AI Character in Taiwan
May 21, 2026 13:55 JST
Hitachi Energy's HMAX Energy service solutions strengthen long-term reliability for Akaysha Energy's Ulinda Park BESS
May 21, 2026 13:40 JST
Heads of State/Government, Ministers, and Senior Officials from 30 Countries to Convene in Tokyo for the Island States Ocean Summit
May 20, 2026 17:00 JST
Trusco Nakayama and Fujitsu accelerate personnel transfer decision-making process with data and AI
May 20, 2026 13:50 JST
Hitachi announces strategic partnership with Anthropic to strengthen "Lumada 3.0" through frontier AI
May 19, 2026 23:09 JST
SMBC Group, Fujitsu and SoftBank agree on alliance to build Japan-made platform for sustainable healthcare
May 19, 2026 13:37 JST
Ashikaga Bank launches Fujitsu's service supporting digitalization of Inheritance Procedure
May 18, 2026 18:13 JST
Sharp to Exhibit at The 3rd SPEXA - Space Business Expo
May 18, 2026 17:34 JST
MHIEC Receives Waste Treatment Technology Verification Report from JESC for Its Fluidized Bed-type Gasification and Reforming System
May 18, 2026 17:17 JST
MHI Thermal Systems Receives A' Design Awards
-- Recognition at Italy's International Design Competition for the Hydrolution EZY Series of Air-to-Water Heat Pumps and the ZT Series of Residential-Use Air-Conditioners --
May 18, 2026 16:26 JST
Tallgrass and Mitsubishi Power Americas Announce Turbine Allocation for Cheyenne Power Hub
May 18, 2026 15:15 JST
JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
May 15, 2026 17:36 JST
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
May 15, 2026 17:12 JST
Fujitsu and IBM Japan formalize collaboration in healthcare sector
May 15, 2026 16:42 JST
Toyota Launches All-New Land Cruiser "FJ" Series in Japan
May 15, 2026 15:24 JST
Mitsubishi Motors Signs Memorandum of Understanding with FPT Japan Holdings to Study Collaboration in Software and Digital Domain
May 15, 2026 15:10 JST
More Latest Release >>